Tepotinib
Back to searchMolecule Structure
Scientific Name
Tepotinib
Description of the Drug
Tepotinib is an oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15133
http://www.drugbank.ca/drugs/DB15133
Brand Name(s)
Not Available
Company Owner(s)
Emd Serono Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Hepatocyte growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL3717 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1296895 |
| Human Metabolome Database | HMDB0304846 |
| DrugBank | DB15133 |
| PubChem: Thomson Pharma | 92728605 |
| PubChem | 25171648 |
| LINCS | LSM-45557 |
| Nikkaji | J3.099.915K |
| PDBe | 3E8 |
| BindingDB | 50065457 |
| EPA CompTox Dashboard | DTXSID70149132 |
| DrugCentral | 5424 |
| ChemicalBook | CB72550731 |
| Guide to Pharmacology | 8293 |
| ZINC | ZINC000043202335 |
